These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22555104)

  • 41. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y; Yang F; Liu JS
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract]   [Full Text] [Related]  

  • 42. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.
    Wong KK; Gershenson D
    Dis Markers; 2007; 23(5-6):377-87. PubMed ID: 18057521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
    Voutsadakis IA
    Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-grade serous ovarian cancer: a unique disease.
    Schmeler KM; Gershenson DM
    Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
    McLachlan J; Gore M; Banerjee S
    Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-grade serous ovarian cancer: State of the science.
    Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM
    Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel therapeutics in low-grade serous ovarian cancer.
    Cobb L; Gershenson D
    Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst - a bridge too far?
    Ramanayake N; Russell P; Yang V
    Pathology; 2018 Aug; 50(5):485-489. PubMed ID: 29960723
    [No Abstract]   [Full Text] [Related]  

  • 50. Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Rankin EB
    Int J Gynecol Cancer; 2019 Aug; 29(Suppl 2):s7-s11. PubMed ID: 31462542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re-assessment of the high-grade serous ovarian cancer phosphoproteome - Identification of kinase candidates in TCGA tumors for future clinical intervention.
    Rolfs F; Piersma SR; Jimenez CR
    EBioMedicine; 2019 Mar; 41():34-35. PubMed ID: 30797713
    [No Abstract]   [Full Text] [Related]  

  • 52. High-grade serous ovarian cancer: the clone wars.
    Salomon-Perzyński A; Salomon-Perzyńska M; Michalski B; Skrzypulec-Plinta V
    Arch Gynecol Obstet; 2017 Mar; 295(3):569-576. PubMed ID: 28154920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
    Quintela M; James DW; Garcia J; Edwards K; Margarit L; Das N; Lutchman-Singh K; Beynon AL; Rioja I; Prinjha RK; Harker NR; Gonzalez D; Steven Conlan R; Francis LW
    Br J Cancer; 2023 Jul; 129(1):163-174. PubMed ID: 37120667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma.
    Beirne JP; McArt DG; James JA; Salto-Tellez M; Maxwell P; McCluggage WG
    Histopathology; 2016 Mar; 68(4):615-8. PubMed ID: 26173002
    [No Abstract]   [Full Text] [Related]  

  • 55. DNA damage repair in ovarian cancer: unlocking the heterogeneity.
    Gee ME; Faraahi Z; McCormick A; Edmondson RJ
    J Ovarian Res; 2018 Jun; 11(1):50. PubMed ID: 29925418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?
    Crum CP; Yoon JY; Feltmate CM
    Gynecol Oncol; 2023 Feb; 169():1-3. PubMed ID: 36459857
    [No Abstract]   [Full Text] [Related]  

  • 58. [Updates on pathogenesis of ovarian tumors].
    Guo XR; Shen DH; Du JR
    Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):627-30. PubMed ID: 19094589
    [No Abstract]   [Full Text] [Related]  

  • 59. Molecular changes driving low-grade serous ovarian cancer and implications for treatment.
    Kelliher L; Yoeli-Bik R; Schweizer L; Lengyel E
    Int J Gynecol Cancer; 2024 Jul; ():. PubMed ID: 38950921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serous ovarian cancer signaling pathways.
    Kotsopoulos IC; Papanikolaou A; Lambropoulos AF; Papazisis KT; Tsolakidis D; Touplikioti P; Tarlatzis BC
    Int J Gynecol Cancer; 2014 Mar; 24(3):410-7. PubMed ID: 24476895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.